Biotest
Sustainability Report and Carbon Intensity Rankings
Is Biotest doing their part?
Their DitchCarbon score is 33
Biotest has a DitchCarbon Score of 33 out of 100, indicating room for improvement in its sustainability practices. This score reflects a higher carbon intensity compared to more sustainable companies. Efforts to reduce emissions and enhance sustainability measures would be beneficial for Biotest to increase its score.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Biotest is a company in the health and social services industry, which has a carbon intensity ranking of low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Biotest, located in Germany, operates in a region with a medium carbon intensity rating. This indicates that the company’s sustainability efforts are influenced by the country’s moderate level of carbon emissions.
Unlock 30+ emissions data points on Biotest
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Biotest
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
8.56%
...this company is doing 8.56% worse in emissions than the industry average.
Founded in 1946 and headquartered in Dreieich, Biotest operates within the health and social services industry, focusing on hematology and immunology. The company employs approximately 2,000 people to develop, manufacture, and distribute medicinal products derived from human blood plasma, as well as hygiene monitoring products. Biotest’s innovative portfolio includes treatments for blood disorders, immune diseases, and research into monoclonal antibodies for autoimmune conditions, serving patients and healthcare providers in 159 countries.
emission intelligence's platform recommendations for Biotest
Biotest should consider investing in cleaner and more efficient machinery and equipment to potentially reduce their scope 1 emissions by 15%.
Bad news, Biotest hasn't committed to SBTi goals yet
Biotest has not established specific commitments with the Science Based Targets initiative (SBTi) to reduce greenhouse gas emissions. This means the company has yet to align its environmental goals with the global effort to limit warming to well below 2 degrees Celsius above pre-industrial levels.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.